US2023172951A1PendingUtilityA1

Methods of using bile acids to treat viral infections

64
Assignee: HOFFMAN TECH LLCPriority: May 14, 2020Filed: May 14, 2021Published: Jun 8, 2023
Est. expiryMay 14, 2040(~13.8 yrs left)· nominal 20-yr term from priority
Inventors:Steven HoffmanJohn Rothman
A61K 31/575A61K 9/4825A01N 45/00A61K 9/007A61K 9/0053A61P 31/14Y02A50/30A61P 31/16
64
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure is directed to methods of using hydrophilic bile acids for the treatment of viral infections.

Claims

exact text as granted — not AI-modified
1 . A method of treating a viral infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a hydrophilic bile acid, wherein the viral infection is not SARS-CoV-2 or SARS-CoV-1. 
     
     
         2 . The method of  claim 1 , wherein the hydrophilic bile acid is tauroursodeoxycholic acid (TUDCA). 
     
     
         3 . The method of  claim 1 , wherein the hydrophilic bile acid is ursodeoxycholic acid (UDCA). 
     
     
         4 . The method of  claim 1 , wherein the hydrophilic bile acid is administered orally. 
     
     
         5 . The method of  claim 1 , wherein the hydrophilic bile acid is administered parenterally. 
     
     
         6 . The method of  claim 1 , wherein the hydrophilic bile acid is administered via inhalation. 
     
     
         7 . The method of  claim 1 , wherein the amount of the hydrophilic bile acid administered to the subject is up to 5 g/day. 
     
     
         8 . The method of  claim 1 , wherein the subject is administered the hydrophilic bile acid twice per day. 
     
     
         9 . The method of  claim 1 , wherein the administration results in a reduction in the subject's viral load, as compared to baseline. 
     
     
         10 . The method of  claim 1 , wherein the administration results in an improvement in one or more of the subject's viral infection symptoms, as compared to baseline. 
     
     
         11 . The method of  claim 1 , wherein the administration results in an improvement in the subject's clinical status, as compared to baseline. 
     
     
         12 . The method of  claim 1 , wherein the viral infection is a respiratory viral infection. 
     
     
         13 . The method of  claim 1 , wherein the viral infection is an influenza virus infection, a parainfluenza virus infection, a rhinovirus infection, a respiratory syncytial virus infection, yellow fever, pseudorabies, or a coronavirus infection that is not SARS-CoV-2 or SARS-CoV-1. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 1 , wherein the viral infection that is an influenza A virus infection. 
     
     
         16 . The method of  claim 1 , wherein the viral infection that is an influenza B virus infection. 
     
     
         17 . The method of  claim 1 , wherein the viral infection that is an influenza C virus infection. 
     
     
         18 . The method of  claim 1 , wherein the viral infection that is a rhinovirus A infection. 
     
     
         19 . The method of  claim 1 , wherein the viral infection that is a rhinovirus B infection. 
     
     
         20 . The method of  claim 1 , wherein the viral infection that is a rhinovirus C infection. 
     
     
         21 . The method of  claim 1 , wherein the viral infection that is a respiratory syncytial virus A infection. 
     
     
         22 . The method of  claim 1 , wherein the viral infection that is a respiratory syncytial virus B infection. 
     
     
         23 .- 44 . (canceled)

Join the waitlist — get patent alerts

Track US2023172951A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.